These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36858841)

  • 1. PCDHA1 High Expression is Associated With Poor Prognosis and Correlated With Immune Cell Infiltration in Breast Cancer.
    Du J; Wu K
    Clin Breast Cancer; 2023 Jun; 23(4):397-407. PubMed ID: 36858841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
    Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
    Song C; Shang F; Tu W; Liu X
    BMC Cancer; 2023 Mar; 23(1):296. PubMed ID: 37004015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.
    Yuan R; Zhang Y; Wang Y; Chen H; Zhang R; Hu Z; Chai C; Chen T
    Front Immunol; 2023; 14():1152678. PubMed ID: 37215111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights.
    Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J
    Front Immunol; 2023; 14():1219652. PubMed ID: 37457713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation.
    Zhao W; Chang Y; Wu Z; Jiang X; Li Y; Xie R; Fu D; Sun C; Gao J
    PeerJ; 2023; 11():e15703. PubMed ID: 37483962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis of prognostic value and immune infiltration of spindle and kinetochore-associated family members in breast cancer.
    Ding J; He X; Wang J; Cao G; Chen S; Yuan L; Chen B; Xiong M
    Bioengineered; 2021 Dec; 12(2):10905-10923. PubMed ID: 34845974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer.
    Yao L; Li Y; Li S; Wang M; Cao H; Xu L; Xu Y
    BMC Cancer; 2023 May; 23(1):440. PubMed ID: 37189064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
    He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
    Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
    Wang Z; Liu H; Gong Y; Cheng Y
    Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
    Liu S; Ye Z; Xue VW; Sun Q; Li H; Lu D
    BMC Cancer; 2023 Apr; 23(1):307. PubMed ID: 37016301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of vesicle-associated membrane protein 7 in breast cancer tissues.
    Huang Y; Wu M; Li JD; Qin Z; Huang KQ; Cui JZ; Ou HL
    Technol Health Care; 2024; 32(4):2141-2157. PubMed ID: 38393934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
    Tang W; Xu F; Zhao M; Zhang S
    BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer.
    Zhang P; Xie X; Li C; Zhang C; Liang P
    Cancer Med; 2023 Oct; 12(19):19758-19776. PubMed ID: 37706625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic biomarkers for breast cancer brain metastases based on the bioinformatics analysis.
    Wu Z; Wan J; Wang J; Meng X; Qian H
    Biochem Biophys Rep; 2022 Mar; 29():101203. PubMed ID: 35059509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGA1 As a Potential Prognostic and Therapeutic Biomarker in Breast Cancer.
    Wang T; Zhou T; Fu F; Han Y; Li Y; Yuan M
    Dis Markers; 2022; 2022():7466555. PubMed ID: 36479041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
    Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L
    Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
    Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
    Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
    Xu Q; Chen S; Hu Y; Huang W
    Front Immunol; 2021; 12():711433. PubMed ID: 34512634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.